3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
62
Breast Neoplasms
42
Prostatic Neoplasms
32
Lung Neoplasms
30
Multiple Myeloma
24
Neoplasms
22
Ovarian Neoplasms
18
Neoplasm Metastasis
18
Colorectal Neoplasms
18
Leukemia, Lymphocytic, Chronic, B-Cell
17
Parkinson Disease 4, Autosomal Dominant Lewy Body
14
Carcinoma, Renal Cell
14
Urinary Bladder Neoplasms
12
Small Cell Lung Carcinoma
12
Endometrial Neoplasms
12
Stomach Neoplasms
11
Pancreatic Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
9
Myasthenia Gravis
9
Lymphoma, Follicular
9
Fallopian Tube Neoplasms
9
Non-Muscle Invasive Bladder Neoplasms
8
Leukemia, Myeloid, Acute
8
Colonic Neoplasms
8
Adenocarcinoma
8
Triple Negative Breast Neoplasms
7
Burkitt Lymphoma
7
Recurrence
6
Lymphoma, Non-Hodgkin
6
Esophageal Neoplasms
6
Interventions
ribociclib
1
palbociclib
1
capivasertib
1
abemaciclib
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Locally Advanced (Inoperable) or Metastatic Breast Cancer
×
30 days
×
Clear all
NCT04862663
2026-05-27
CAPItello-292
AstraZeneca
Phase 3
Recruiting
895 enrolled